Johnson & Johnson
在场
是其中之一......
- Forbes Global 2000 (#45);
- Fortune 500 (#42);
- Global Fortune 500 (#115);
- Russell 3000;
- S&P 500;
- TOB Iconic 10,000.
Johnson & Johnson 是一家在股票代码 JNJ (US) 下上市的公司。
Johnson & Johnson 在 23 个国家有直接业务。Johnson & Johnson 拥有 65家子公司，其中包括 Abiomed、Ambrx 和 DePuy Synthes。
他们在：
涉及Johnson & Johnson的并购和融资。
- Johnson & Johnson 已收购 V-Wave (公布2024十月9号).
- Johnson & Johnson has announced the acquisition of Proteologix (公布2024六月21号).
- Johnson & Johnson has announced the acquisition of Proteologix (公布2024五月20号).
- Johnson & Johnson has announced the acquisition of Shockwave Medical (公布2024四月6号).
- Johnson & Johnson 已收购 Ambrx (公布2024一月11号).
- 查看更多"Johnson & Johnson"相关新闻 Hide news involving Johnson & Johnson
高管
查看带有其 463 名主要高管的组织结构图
Johnson & Johnson 搜索最多的简介
- Joaquin Duato, Chief Executive Officer and Chairman of the Board
- Jennifer Doudna, Director
- Marillyn Hewson, Director
高管在Johnson & Johnson变化
- Scott Davis, Director, 正在办理退休 (新闻发布的2024九月11号).
- Kristen Mulholland 曾任 Head of Human Resources, Global Total Rewards, 将于 202410月1 升职为 Chief Human Resources Officer (新闻发布的2024八月26号).
- Peter Fasolo, Executive Vice President and Chief Human Resources Officer, 将于 202410月1 退休 (新闻发布的2024八月26号).
创建提醒
跟踪 Johnson & Johnson 的高管变动
药店
Johnson & Johnson 拥有 1,833 家竞争者，其中包括 Pfizer (美国(美洲))、Sanofi (法国) 和 Roche (瑞士)。
Popular M&A news in 药店
- Stemtech and Seacret Direct have announced they will merge (公布2024十二月5号)..
- Recursion Pharma and Exscientia have merged (公布2024十一月27号)..
- Stemtech and Seacret Direct have announced they will merge (公布2024十一月22号)..
药店 行业的其他推荐联系人
消息
Johnson & Johnson 的最新新闻稿
- Johnson & Johnson seeks U.S. FDA approval for subcutaneous induction regimen of TREMFYA® (guselkumab) in ulcerative colitis, a first for an IL-23 inhibitor
- Icotrokinra delivered an industry-leading combination of significant skin clearance with demonstrated tolerability in a once daily pill in Phase 3 topline results
- Johnson & Johnson to showcase strength of its broad hematology portfolio and pipeline at the 2024 American Society of Hematology Annual Meeting
- DARZALEX® (daratumumab)-SC based quadruplet regimen approved by the European Commission for patients with newly diagnosed multiple myeloma who are transplant-eligible
- https://twitter.com/jnjnews
- Latest News | Johnson & Johnson
- Janssen Submits Supplemental New Drug Application to U.S. FDA for SPRAVATO® (esketamine) CIII Nasal Spray for the Rapid Reduction of Depressive Symptoms in Adults with Major Depressive Disorder Who Have Active Suicidal Ideation with Intent | Johnson & Joh
- New Data from Esketamine Nasal Spray Phase 3 Studies Showed Rapid Reduction of Depressive Symptoms in Adult Patients with Major Depressive Disorder Who Have Active Suicidal Ideation with Intent | Johnson & Johnson
- New Real-World Evidence Highlights Need for Interventions to Improve Outcomes for Patients Who Have Been Diagnosed with Major Depressive Disorder (MDD) and Suicide Ideation or Attempt | Johnson & Johnson
- New Data Highlights the Value of SPRAVATO™ (esketamine) CIII Nasal Spray, the First New Antidepressant in Decades that Works Differently for Adults with Treatment-Resistant Depression (TRD)[i] | Johnson & Johnson
- View more press releases Close
通过电子邮件
